Molecualr profiling for pancreatic cacner – pro
NCCN Panc-1, 2025 says: ” Molecular profiling of tumor tissue is “recommended. It further deines its recommendation: ” Tumor/somatic molecular profiling, preferably using a next-generation sequencing (NGS) assay, is recommended for patients with locally advanced/metastatic disease who are candidates for anti-cancer therapy to identify clinically actionable and/or emerging alterations. These alterations include, but are not limited to: fusions (ALK,
NRG1, NTRK, ROS1, FGFR2, and RET), mutations (BRAF, BRCA1/2, KRAS, and PALB2), amplifications (HER2), microsatellite instability (MSI), mismatch repair deficiency (dMMR), or tumor mutational burden (TMB) using comprehensive genomic profiling via an FDA-approved and/or validated NGS-based assay, and HER2
overexpression via IHC ± FISH. RNA sequencing assays are preferred for detecting RNA fusions because gene fusions are better detected by RNA-based NGS. Testing on tumor tissue is preferred; however, cell-free DNA testing can be considered if tumor tissue testing is not feasible. See Discussion and Principles of Cance” in footnote J.j
NCCN Panc-1, 2025
Zhen DB, Safyan RA, Konick EQ, Nguyen R, Prichard CC, Chiorean EG. The role of molecular testing in pancreatic cancer. Therap Adv Gastroenterol. 2023 May 12;16:17562848231171456. doi: 10.1177/17562848231171456. PMID: 37197396; PMCID: PMC10184226.
Mota Reyes C, Doğruöz A, Istvanffy R, Friess H, Ceyhan GO, Demir IE. Molecular Profiling in Pancreatic Cancer: Current Role and Its Impact on Primary Surgery. Visc Med. 2022 Feb;38(1):37-41. doi: 10.1159/000519755. Epub 2021 Oct 26. PMID: 35295890; PMCID: PMC8874240.